XL-184 free base (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. In cells XL-184 free base (Cabozantinib) is also very potent, with IC50 under 10 nM for VEGFR2, MET, Kit and FLT3-ITD mechanistic assays. In in vitro angiogenesis assays, XL-184 free base (Cabozantinib) exhibits single-digit nanomolar potency. In mouse xenograft models, XL-184 free base (Cabozantinib), dosed orally, demonstrated dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis

June 21, 2017

prudect name : XL-184 free base (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. In cells XL-184 free base (Cabozantinib) is also very potent, with IC50 under 10 nM for VEGFR2, MET, Kit and FLT3-ITD mechanistic assays. In in vitro angiogenesis assays, XL-184 free base (Cabozantinib) exhibits single-digit nanomolar potency. In mouse xenograft models, XL-184 free base (Cabozantinib), dosed orally, demonstrated dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis
Cabozantinib (S)-malate

Synonyms: CAS NO: 1140909-48-3Molecular Formula: C₂₈H₂₄FN₃O₅.C₄H₆O₅Molecular Weight: 635.60Purity: 99%Solubility: In DMSOStorage: -20°C

GW-4064 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18507865